Epigenetic drugs that have shown promise in cancer trials significantly reduce scarring in the cells of patients with scleroderma, a new study shows. Results reveal that drugs that inhibit BRD4, known to play a role in cancer, also affect fibrosis in scleroderma. Researchers tested BRD4 inhibitors on the skin fibroblasts of scleroderma patients and in mouse models of skin fibrosis, finding that the treatment stopped scarring in both human-derived cells and in animals.